Adding pembrolizumab to THP improved pCR rates in patients with HER2-positive breast cancer in the phase 2 NeoHIP trial.

Based on the results of this study, current recommendations suggest that TNBC patients with tumors larger than 2 cm or with ...

A study led by Roswell Park Comprehensive Cancer Center provides new insight into the complex interactions of the ...

TuHURA Biosciences, Inc. (Nasdaq: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies ...

Josep M. Llovet, MD, PhD, describes the phase 3 LEAP-012 clinical study, including its methods, design, and enrollment criteria.

Data shows strong overall survival, progression-free survival, and durability from novel combination of efti in combination with pembrolizumab in ...

Topline results were announced from a phase 3 trial investigating a subcutaneous formulation of pembrolizumab, a programmed death receptor-1-blocking antibody, with berahyaluronidase alfa ...

Pembrolizumab plus fulvestrant provided disease control in 50% of patients with ER-positive, HER2-negative metastatic breast cancer.

The trial is evaluating the noninferiority of subcutaneous administration of pembrolizumab, Merck’s anti-PD-1 therapy, available for intravenous use as KEYTRUDA ®, together with ...

An exploratory analysis of the KEYNOTE-522 study presented at the 2024 San Antonio Breast Cancer Symposium highlights ...

Investigators were seeking clarification on optimal sequencing of the immune checkpoint inhibitor atezolizumab following ...

Petosemtamab in combination with pembrolizumab in 1L r/m PD-L1 expressing HNSCC ongoing with clinical data update planned for 2025 Petosemtamab in mCRC evaluation expanded to include 1L and 3L+; ...